Tirzepatide and eyelid styes: what's known

A case series published in JCEM Case Reports in September 2026 describes two women who developed multiple eyelid lumps, styes known clinically as hordeola, while taking tirzepatide, the dual GIP and GLP-1 receptor agonist sold as Mounjaro and Zepbound. In both patients some of the lesions progressed into chalazia, longer-lasting cysts from a blocked eyelid gland. In one patient the bumps cleared after she stopped the drug and came back when she restarted it^[1]. The authors describe it as the first reported case series tying this eyelid pattern to tirzepatide. Two patients is not enough to say the drug causes eyelid styes in general, and the authors are careful to say so. It is enough to be worth knowing about if you are on the drug and notice something unusual around your eyes.

What the case series found

The first patient, a 44-year-old woman with a body-mass index of 25.6, developed six upper-eyelid hordeola at the same time, about four weeks after her dose was raised to 5 mg weekly. Five of the six went on to become chalazia. None of the usual signs of infection were present: no redness along the lid margin, no crusting, no visible blood vessels. When she stopped tirzepatide, the lesions improved. When she restarted it, they enlarged and became symptomatic again^[1]. Clinicians call that pattern a positive dechallenge and rechallenge, and it is one of the stronger forms of evidence a single case can offer that a drug caused the reaction and coincidence did not.

The second patient, a 73-year-old woman with a body-mass index of 28.9 and pre-existing mild blepharitis (a chronic eyelid-margin irritation unrelated to tirzepatide), developed six simultaneous hordeola about ten weeks after reaching the 5 mg dose. Two progressed to chalazia. Her lesions improved with treatment, then recurred five months later along with two further, self-limited hordeola. Because she already had blepharitis, her case is a weaker signal on its own; the authors scored it as a "possible" reaction rather than the "probable" rating given to the first patient^[1].

Stye or chalazion: a quick glossary

A stye, or hordeolum, is a painful, pus-filled lump caused by a bacterial infection of an eyelid gland. It comes on quickly. A chalazion is different: it forms when an oil-producing gland in the eyelid (a meibomian gland) becomes blocked and inflamed over a longer period, it is usually painless, and it does not involve pus^[2]. Both patients in this case series had lesions that looked and behaved like sterile obstructions rather than infections. The gland openings were mildly congested, nothing could be expressed from the glands, and there was no discharge. That pattern points toward blocked glands, not bacteria, as the underlying process^[1].

Why tirzepatide might affect eyelid glands

Meibomian glands make an oily secretion (meibum) that keeps the tear film stable. Normal gland function depends on ongoing lipid production and a duct that stays open; anything that thickens the oil or narrows the duct can lead to a backup, which is the underlying process in most meibomian gland disease^[3]. The case series authors propose two possible mechanisms specific to tirzepatide. First, GIP and GLP-1 receptor activity may suppress a pathway (SREBP-1) involved in fat production, which could make meibum thicker and more prone to clogging the duct. Second, the rapid fat loss tirzepatide produces, including around the eyes, a pattern some clinicians now call "GLP-1 face," could physically compress or distort the gland ducts^[1]. Neither mechanism has been tested directly. Both are proposed explanations for a pattern seen in two patients, not confirmed biology.

How strong is this evidence, really

A two-patient case series sits near the bottom of the evidence hierarchy. It cannot tell you how often this happens, whether it happens more in some patients than others, or whether it happens at all beyond these two cases. The tirzepatide label, as reflected in the current FDA prescribing information, does not list eyelid gland problems among its adverse reactions^[4], which is consistent with something this specific being genuinely rare, being under-recognized, or both. What raises this particular case series above an anecdote is the dechallenge and rechallenge in the first patient: symptoms that track a drug on, off, and back on again are harder to explain by coincidence than a single unexplained flare. The authors scored that case a 6 on the Naranjo scale, a standardized checklist doctors use to rate how likely it is that a drug caused a specific reaction; a 6 falls in the "probable" range, one tier below "definite," which would require a formal rechallenge under controlled conditions^[1]. The second case scored a 3, "possible," partly because pre-existing blepharitis offers an alternative explanation. Neither score amounts to proof, and the authors call for wider pharmacovigilance reporting so a real incidence estimate can eventually be built.

What this means if you're on tirzepatide

The case-series authors do not recommend stopping tirzepatide over eyelid bumps. Their advice is to try conservative eye care first: warm compresses and eyelid hygiene, the same first-line approach used for ordinary styes and chalazia^[2]. They suggest clinicians reserve a conversation about changing the tirzepatide regimen for cases that do not respond to that conservative approach, given how much the drug is doing for a patient's diabetes or weight-related health. If you notice a new eyelid lump or several at once while on tirzepatide or a related drug such as semaglutide, mention it to your prescriber or an eye doctor instead of assuming it will resolve on its own or deciding to stop the medication yourself.

This article is for educational and journalistic purposes and does not replace individual medical advice. Whether a new eyelid symptom is related to a medication you are taking, and what to do about it, is a question for a clinician who can examine you.